CL2023003038A1 - Derivados de benzo[d][1,3]dioxol como activadores del receptor glp1 para tratamiento de obesidad - Google Patents
Derivados de benzo[d][1,3]dioxol como activadores del receptor glp1 para tratamiento de obesidadInfo
- Publication number
- CL2023003038A1 CL2023003038A1 CL2023003038A CL2023003038A CL2023003038A1 CL 2023003038 A1 CL2023003038 A1 CL 2023003038A1 CL 2023003038 A CL2023003038 A CL 2023003038A CL 2023003038 A CL2023003038 A CL 2023003038A CL 2023003038 A1 CL2023003038 A1 CL 2023003038A1
- Authority
- CL
- Chile
- Prior art keywords
- compounds
- activators
- obesity
- treatment
- benzo
- Prior art date
Links
- 208000008589 Obesity Diseases 0.000 title abstract 2
- 239000012190 activator Substances 0.000 title abstract 2
- 235000020824 obesity Nutrition 0.000 title abstract 2
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical class C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 title 1
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 title 1
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 4
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 206010003658 Atrial Fibrillation Diseases 0.000 abstract 1
- 208000031229 Cardiomyopathies Diseases 0.000 abstract 1
- 208000002249 Diabetes Complications Diseases 0.000 abstract 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 abstract 1
- 206010012655 Diabetic complications Diseases 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 208000002705 Glucose Intolerance Diseases 0.000 abstract 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 abstract 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 208000029078 coronary artery disease Diseases 0.000 abstract 1
- 208000033679 diabetic kidney disease Diseases 0.000 abstract 1
- -1 for example Chemical class 0.000 abstract 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 abstract 1
- 201000008980 hyperinsulinism Diseases 0.000 abstract 1
- 201000001119 neuropathy Diseases 0.000 abstract 1
- 230000007823 neuropathy Effects 0.000 abstract 1
- 208000033808 peripheral neuropathy Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención se refiere a compuestos de la fórmula (I) como activadores del receptor del péptido 1 similar al glucagón (GLP1) para el tratamiento de la obesidad, diabetes mellitus tipo 2, resistencia a la insulina, hiperinsulinemia, intolerancia a la glucosa, hiperglucemia, una o más complicaciones diabéticas, nefropatía diabética, dislipidemia, enfermedad del hígado graso no alcohólico (NAFLD), esteatohepatitis no alcohólica (NASH), hipertensión, aterosclerosis, enfermedad arterial periférica, accidente cerebrovascular, miocardiopatía, fibrilación auricular, insuficiencia cardíaca, enfermedad coronaria y neuropatía. Los compuestos preferidos son, por ejemplo, derivados de compuesto de la fórmula (I) y compuestos similares, tales como, por ejemplo, C-1, C-2, C-3, C-4 y otros compuestos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163173592P | 2021-04-12 | 2021-04-12 | |
| US202263308843P | 2022-02-10 | 2022-02-10 | |
| US202263323401P | 2022-03-24 | 2022-03-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023003038A1 true CL2023003038A1 (es) | 2024-05-03 |
Family
ID=81308304
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023003038A CL2023003038A1 (es) | 2021-04-12 | 2023-10-11 | Derivados de benzo[d][1,3]dioxol como activadores del receptor glp1 para tratamiento de obesidad |
Country Status (3)
| Country | Link |
|---|---|
| CL (1) | CL2023003038A1 (es) |
| TW (1) | TW202304891A (es) |
| WO (1) | WO2022219495A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022028572A1 (en) | 2020-08-06 | 2022-02-10 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| WO2023106310A1 (ja) * | 2021-12-07 | 2023-06-15 | 塩野義製薬株式会社 | Ｇｌｐ－１受容体アゴニスト活性を有する芳香族複素環誘導体 |
| WO2023111145A1 (en) | 2021-12-16 | 2023-06-22 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
| WO2023111144A1 (en) | 2021-12-16 | 2023-06-22 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
| WO2024102625A1 (en) | 2022-11-11 | 2024-05-16 | Eli Lilly And Company | Glucagon-like peptide 1 receptor agonists |
| WO2024107781A1 (en) | 2022-11-16 | 2024-05-23 | Eli Lilly And Company | Glucagon-like peptide 1 receptor agonists |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200303742A (en) | 2001-11-21 | 2003-09-16 | Novartis Ag | Organic compounds |
| CN1795193B (zh) | 2003-05-20 | 2010-08-18 | 诺瓦提斯公司 | 用作过氧化物酶体增殖物激活受体的配体的n-酰基含氮杂环化合物 |
| CA2832581C (en) | 2011-04-08 | 2022-08-23 | Yumei Xiong | Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15) |
| EP2807266B1 (en) | 2012-01-26 | 2020-01-15 | Amgen Inc. | Growth differentiation factor 15 (gdf-15) polypeptides |
| WO2013148117A1 (en) | 2012-03-27 | 2013-10-03 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
| BR112015018104A2 (pt) | 2013-01-30 | 2017-11-21 | Ngm Biopharmaceuticals Inc | polipeptídeos de gdf15 modificados, seu uso, composições compreendendo os mesmos e recipiente estéril compreendendo as referidas composições |
| US9161966B2 (en) | 2013-01-30 | 2015-10-20 | Ngm Biopharmaceuticals, Inc. | GDF15 mutein polypeptides |
| BR112016002213A2 (pt) | 2013-07-31 | 2017-08-29 | Amgen Inc | Construtos do fator 15 de diferenciação de crescimento (gdf-15) |
| US20170204149A1 (en) | 2014-06-23 | 2017-07-20 | Novartis Ag | Hsa-gdf-15 fusion polypeptide and use thereof |
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| AU2015279525A1 (en) | 2014-06-24 | 2016-12-15 | Novo Nordisk A/S | MIC-1 fusion proteins and uses thereof |
| EP3393494A1 (en) | 2015-12-22 | 2018-10-31 | Novartis Ag | Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15) |
| US10934279B2 (en) | 2018-06-13 | 2021-03-02 | Pfizer Inc. | GLP-1 receptor agonists and uses thereof |
| US20220387402A1 (en) * | 2019-05-20 | 2022-12-08 | Pfizer Inc. | Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases |
| WO2022028572A1 (en) * | 2020-08-06 | 2022-02-10 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
-
2022
- 2022-04-11 WO PCT/IB2022/053367 patent/WO2022219495A1/en active Application Filing
- 2022-04-12 TW TW111113837A patent/TW202304891A/zh unknown
-
2023
- 2023-10-11 CL CL2023003038A patent/CL2023003038A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022219495A1 (en) | 2022-10-20 |
| TW202304891A (zh) | 2023-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023003038A1 (es) | Derivados de benzo[d][1,3]dioxol como activadores del receptor glp1 para tratamiento de obesidad | |
| PE20220590A1 (es) | Agonistas del receptor del peptido-1 similar al glucagon | |
| CU20160189A7 (es) | Ácidos grasos útiles en la conjugación con biomoléculas | |
| TW202313586A (zh) | Glp-1受體激動劑及其用途 | |
| EP2366699B1 (en) | 8-substituted isoquinoline derivative and use thereof | |
| RU2490250C2 (ru) | Спиросоединения и их фармацевтическое применение | |
| CN107847495A (zh) | K‑Ras调节剂 | |
| CO6410287A2 (es) | Composición farmacéutica, forma farmacéutica, procedimiento para su preparación, métodos de tratamiento y usos de la misma | |
| WO2022031994A1 (en) | Glp-1r agonists and uses thereof | |
| BR112013021236A8 (pt) | composto, composição,e, método de tratamento de um distúrbio, uma condição ou uma doença | |
| BRPI0516446A (pt) | combinação de compostos orgánicos | |
| PE20080522A1 (es) | Derivados de indol como inhibidores de los transportadores de glucosa dependientes de sodio (sglt) | |
| CU20130073A7 (es) | Péptidos derivados del factor de crecimiento de fibroblastos 21 ( fgf21) útiles como reguladores metabólicos | |
| PE20090987A1 (es) | Composicion farmaceutica que comprende un derivado de pirazol-o-glucosido | |
| GT200600429A (es) | Compuestos organicos | |
| NZ603644A (en) | Bicyclic heteroaryl kinase inhibitors and methods of use | |
| BR112022000027A2 (pt) | Compostos agonistas gipr | |
| BR112015003109A2 (pt) | Composto, composição, uso de um composto, e, métodos para tratar ou prevenir um distúrbio, condição ou doença e para tratar diabetes mellitus tipo 2. | |
| AR064489A1 (es) | Derivados de ciclohexil-metilamina, composiciones farmaceuticas y productos que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la dipeptidil-peptidasa (dpp-iv) | |
| US20120040897A1 (en) | Novel derivatives of acyl cyanopyrrolidines | |
| TWI786467B (zh) | Glp-1受體激動劑及其用途 | |
| CR20210085A (es) | Compuestos de 2,6-diaminopiridina | |
| WO2016060517A2 (ko) | 신규한 3-(4- (벤질옥시)페닐)핵스- 4-이노익 산 유도체 및 다른 유효 성분을 포함하는 대사성 질환의 예방 또는 치료용 복합제제 | |
| Sun et al. | PEGylated exendin-4, a modified GLP-1 analog exhibits more potent cardioprotection than its unmodified parent molecule on a dose to dose basis in a murine model of myocardial infarction | |
| CN102159586A (zh) | C-芳基葡糖苷衍生物、其制备方法及其在医药上的应用 |